Literature DB >> 26923395

Seed loss in prostate brachytherapy : Operator dependency and impact on dosimetry.

Nancy El-Bared1, Natanel Sebbag1, Dominic Béliveau-Nadeau1, Yannick Hervieux1, Renée Larouche1, Daniel Taussky2, Guila Delouya1.   

Abstract

INTRODUCTION: The aim of our study was to review seed loss and its impact on dosimetry as well as the influence of the treating physician on seed loss and dosimetry in patients treated with prostate brachytherapy using permanent loose (125)I implant. PATIENTS AND METHODS: We analyzed 1087 consecutive patients treated by two physicians between July 2005 and April 2015 at a single institution. Pelvic fluoroscopic imaging was done 30 days post implant and a chest X-ray when seed loss was observed.
RESULTS: Seed loss occurred in 19.4 % of patients: in 20.0 % of implants done by the most experienced physician and in 17.2 % by the less experienced physician (p = 0.4) and migration to the thorax occurred in 5.9 % (6.9 vs. 2.2 %, p = 0.004). The mean seed loss rate was 0.57 % [standard deviation (SD) 1.39] and the mean rate of seeds in the thorax was 0.14 % (SD 0.65). The most experienced physician had a higher mean number of seeds lost: 0.36 versus 0.25 (p = 0.055), and a higher mean number of seed migration to the thorax: 0.1 versus 0.02 (p < 0.001). When at least one seed was lost, a decrease of 4.2 Gy (p < 0.001) in the D90 and a decrease of 3.5 % (p = 0.002) in the V150 was observed.
CONCLUSION: We found a significant decrease in V150 and D90 with the occurrence of seed loss. Furthermore, we found a difference in seed migration among the physicians demonstrating that seed loss is operator dependant.

Entities:  

Keywords:  Complications; Implant radiotherapy; Learning curve; Radiation dose; Seed migration to thorax

Mesh:

Year:  2016        PMID: 26923395     DOI: 10.1007/s00066-016-0961-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  19 in total

1.  Prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors.

Authors:  Donald B Fuller; James A Koziol; Anne C Feng
Journal:  Brachytherapy       Date:  2004       Impact factor: 2.362

2.  The robustness of dose distributions to displacement and migration of 125I permanent seed implants over a wide range of seed number, activity, and designs.

Authors:  Luc Beaulieu; Louis Archambault; Sylviane Aubin; E Oral; Richard Taschereau; Jean Pouliot
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-15       Impact factor: 7.038

3.  A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer.

Authors:  Yutaka Shiraishi; Atsunori Yorozu; Toshio Ohashi; Kazuhito Toya; Shiro Saito; Toru Nishiyama; Yasuto Yagi; Naoyuki Shigematsu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-12-01       Impact factor: 7.038

4.  Effects of seed migration on post-implant dosimetry of prostate brachytherapy.

Authors:  M Gao; J Z Wang; S Nag; N Gupta
Journal:  Med Phys       Date:  2007-02       Impact factor: 4.071

5.  Analysis of seed loss and pulmonary seed migration in patients treated with virtual needle guidance and robotic seed delivery.

Authors:  Lara Hathout; David Donath; Camille Moumdjian; Audrey Tétreault-Laflamme; Renée Larouche; Dominic Béliveau-Nadeau; Yannick Hervieux; Daniel Taussky
Journal:  Am J Clin Oncol       Date:  2011-10       Impact factor: 2.339

6.  Investigating the dosimetric and tumor control consequences of prostate seed loss and migration.

Authors:  Courtney Knaup; Panayiotis Mavroidis; Carlos Esquivel; Sotirios Stathakis; Gregory Swanson; Dimos Baltas; Nikos Papanikolaou
Journal:  Med Phys       Date:  2012-06       Impact factor: 4.071

7.  PSA recurrence after brachytherapy for seed misplacement: a double-blind radiologic and pathologic work-up after salvage prostatectomy.

Authors:  M Gacci; S Serni; A Lapini; G Vittori; G Vignolini; G Nesi; M Carini
Journal:  Prostate Cancer Prostatic Dis       Date:  2007-10-09       Impact factor: 5.554

8.  Migration of implanted free radioactive seeds for adenocarcinoma of the prostate using a Mick applicator.

Authors:  Charles A Kunos; Martin I Resnick; Timothy J Kinsella; Rodney J Ellis
Journal:  Brachytherapy       Date:  2004       Impact factor: 2.362

9.  Definition of medical event is to be based on the total source strength for evaluation of permanent prostate brachytherapy: A report from the American Society for Radiation Oncology.

Authors:  Subir Nag; D Jeffrey Demanes; Michael Hagan; Mark J Rivard; Bruce R Thomadsen; James S Welsh; Jeffrey F Williamson
Journal:  Pract Radiat Oncol       Date:  2011-10

10.  Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review.

Authors:  Simon Zuber; Susan Weiß; Dieter Baaske; Michael Schöpe; Simon Stevens; Stephan Bodis; Daniel R Zwahlen
Journal:  Radiat Oncol       Date:  2015-02-22       Impact factor: 3.481

View more
  3 in total

1.  Is intraoperative real-time dosimetry in prostate seed brachytherapy predictive of biochemical outcome?

Authors:  Daniel Taussky; Levon Igidbashian; David Donath; Dominic Béliveau-Nadeauv; Renée X Larouche; Yanick Hervieux; Guila Delouya
Journal:  J Contemp Brachytherapy       Date:  2017-06-22

2.  Treatment of low-risk prostate cancer: a retrospective study with 477 patients comparing external beam radiotherapy and I-125 seeds brachytherapy in terms of biochemical control and late side effects.

Authors:  Matthias Moll; Christopher Paschen; Alexandru Zaharie; Florian Berndl; Gregor Goldner
Journal:  Strahlenther Onkol       Date:  2020-07-08       Impact factor: 3.621

3.  Investigating the displacement of radio-active sources during gold-198 grain brachytherapy for hospitalized oral cancer patients.

Authors:  Masaru Konishi; Yuki Takeuchi; Katsumaro Kubo; Nobuki Imano; Ikuno Nishibuchi; Yuji Murakami; Kiichi Shimabukuro; Pongsapak Wongratwanich; Naoya Kakimoto; Yasushi Nagata
Journal:  J Contemp Brachytherapy       Date:  2022-03-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.